Edition:
India

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

15.81USD
22 Jun 2018
Change (% chg)

$-0.70 (-4.24%)
Prev Close
$16.51
Open
$16.56
Day's High
$16.56
Day's Low
$15.60
Volume
1,780,337
Avg. Vol
872,829
52-wk High
$17.60
52-wk Low
$9.53

Latest Key Developments (Source: Significant Developments)

Amicus Therapeutics Expects 2018 Net Cash Spend Of $230 Mln To $260 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS PROVIDES FULL-YEAR 2018 STRATEGIC OUTLOOK AND FINANCIAL GUIDANCE.AMICUS THERAPEUTICS SEES GALAFOLD FY 2018 REVENUE $75 MILLION TO $85 MILLION.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES TOTALED ABOUT $359 MILLION AT DEC 31, 2017.EXPECTS FULL-YEAR 2018 NET CASH SPEND OF BETWEEN $230 MILLION AND $260 MILLION.CURRENT CASH POSITION IS ANTICIPATED TO FUND ONGOING OPERATIONS INTO AT LEAST SECOND HALF OF 2019.FY2018 REVENUE VIEW $88.9 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Amicus Therapeutics Submits New Drug Application To U.S. FDA For Migalastat
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE.AMICUS THERAPEUTICS INC - ‍LOOK FORWARD TO POTENTIAL U.S. APPROVAL OF MIGALASTAT IN 2018​.  Full Article

Amicus Therapeutics Q3 loss per share $0.69
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Amicus Therapeutics Inc ::Amicus therapeutics announces third quarter 2017 financial results and corporate updates.Q3 loss per share $0.69.Q3 revenue $10.9 million versus I/B/E/S view $9.5 million.Q3 adjusted loss per share $0.41 excluding items.Q3 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S.Amicus Therapeutics Inc - ‍reiterated full-year 2017 financial guidance​.Amicus Therapeutics Inc - ‍current cash position anticipated to fund ongoing operations into at least H2 2019​.  Full Article

Vanguard Group reports 5.85 percent passive stake in Amicus Therapeutics as of December 31, 2016
Thursday, 9 Feb 2017 

Vanguard Group Inc :Vanguard Group Inc reports a 5.85 percent passive stake in Amicus Therapeutics Inc as of December 31, 2016 -SEC filing.  Full Article

Amicus Therapeutics Q2 loss per share $0.40
Tuesday, 9 Aug 2016 

Amicus Therapeutics Inc : Amicus therapeutics announces second quarter 2016 financial results and corporate updates . Q2 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.40 . Company expects to remain within original 2016 net cash spend guidance of between $135 million and $155 million. .Reiterated full-year 2016 net cash spend guidance.  Full Article

Amicus therapeutics says it has raised $4.7 mln in equity financing
Wednesday, 20 Jul 2016 

Amicus Therapeutics Inc :says it has raised $4.7 million in equity financing from total offering amount of $4.7 million - Sec filing.  Full Article

Amicus expands pipeline with new program for CDKl5 deficiency
Thursday, 7 Jul 2016 

Amicus Therapeutics : Acquisition of Miamed does not impact previous full-year 2016 net cash spend guidance of $135 million to $155 million . Former shareholders of Miamed are also eligible to receive up to $65 million upon achievement of commercial milestones . Expands biologics pipeline with new preclinical program for cyclin-dependent Kinase-like 5 (cdkl5) deficiency . Obtained rights and related intellectual property to a preclinical CDKl5 program through acquisition of Miamed Inc . Amicus paid approximately $1.8 million in cash and approximately $4.7 million in amicus common stock to former shareholders of Miamed .Former shareholders of Miamed are eligible to receive up to $18 million upon achievement of clinical and regulatory milestones.  Full Article

BRIEF-Amicus Therapeutics Reports Q1 Loss Per Share Of $0.28

* AMICUS THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATES